At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CRDF Cardiff Oncology, Inc.
Post-Market Trading 11-04 16:43:01 EST
3.74
+0.54
+16.69%
盘后3.69
-0.05-1.34%
16:41 EST
High3.79
Low3.06
Vol1.78M
Open3.20
D1 Closing3.21
Amplitude22.78%
Mkt Cap174.10M
Tradable Cap161.47M
Total Shares46.55M
T/O6.43M
T/O Rate4.13%
Tradable Shares43.17M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Cardiff Oncology publishes onvansertib combination data in journal
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.